EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Atara Biotherapeutics's Enterprise Value is $183.58 Mil.
Atara Biotherapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2022 was $-252.09 Mil. Therefore, Atara Biotherapeutics's EV-to-FCF for today is -0.73.
The historical rank and industry rank for Atara Biotherapeutics's EV-to-FCF or its related term are showing as below:
ATRA'
s EV-to-FCF Range Over the Past 10 Years
Min: -6.93 Med: -4.53 Max: -0.16
Current: -0.71
During the past 10 years, the highest EV-to-FCF of Atara Biotherapeutics was -0.16. The lowest was -6.93. And the median was -4.53.
ATRA's EV-to-FCF is ranked worse than 100% of 382
companies
in the Biotechnology industry
Industry Median: 3.44
vs ATRA: -0.71
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2022-08-19), Atara Biotherapeutics's stock price is $4.49.
Atara Biotherapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 was $-2.550. Therefore, Atara Biotherapeutics's PE Ratio for today is At Loss.
Competitive Comparison
For the Biotechnology subindustry, Atara Biotherapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Atara Biotherapeutics EV-to-FCF Distribution
For the Biotechnology industry and Healthcare sector, Atara Biotherapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Atara Biotherapeutics's EV-to-FCF falls into.
Atara Biotherapeutics EV-to-FCF Calculation
Atara Biotherapeutics's EV-to-FCF for today is calculated as:
Atara Biotherapeutics's current Enterprise Value is $183.58 Mil.
Atara Biotherapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-252.09 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Atara Biotherapeutics's PE Ratio for today is calculated as:
Atara Biotherapeutics's share price for today is $4.49.
Atara Biotherapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.550.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Atara Biotherapeutics EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Atara Biotherapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. The company's product candidates comprise Tab-cel, ATA188, and CAR T Programs.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.25(5.27%) Volume: 652,359 1:15PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:ATRA has been successfully added to your 
